摘要
目的:评价依折麦布联合阿托伐他汀对常规剂量他汀药物血脂控制不佳的冠心病患者的疗效。方法:选择服用常规剂量他汀药物血脂控制不佳的冠心病患者126例,随机分为依折麦布联合他汀药物治疗组62例(依折麦布10mg/d+阿托伐他汀10mg/d)和双倍剂量他汀药物治疗组64例(阿托伐他汀20mg/d)。持续24周测定两组患者的总胆固醇(TC),LDL-C,高密度脂蛋白胆固醇(HDL-C),菜油甾醇,7-烯胆甾烷醇和血浆前蛋白转化酶枯草溶菌素9(PSCK9)的含量的变化。结果:联合依折麦布治疗组LDL-C水平,菜油甾醇/7-烯胆甾烷醇比例和PSCK9水平明显低于双倍剂量阿托伐他汀治疗组。双倍剂量阿托伐他汀治疗组LDL-C水平在12周后逐渐回升而联合依折麦布治疗组LDL-C水平降低较为平稳。结论:对常规他汀剂量血脂控制不佳的患者联合依折麦布能有效抑制胆固醇的吸收和合成并且降低LDL-C效果明显优于单纯加大他汀药物剂量。
Objective： To assess LDL-C-lowering effect of ezetimibe-plus-atorvastatin in patients with coronary artery disease whole LDL-C levels were ≥70mg/dl after received conventional-dose statin. Method： Those patients （ n=126 ） were randomly divided into two group and one of groups （ n=62 ） received ezetimible 10 mg/d ＋ atorvastatin 10 mg/d the other group （ n=64 ） received double-dose atorvastatin （ 20 mg/d ） . The plasma of total cholesterol （ TC ）, LDL-C, HDL-C, campesterol, lathosterol and protein convertase subtilisin/kexin type 9 （ PSCK9 ） of two groups were determined for 24 weeks. Result： The levels of LDL-C, PSCK9 and campesterol/lathosterol ratio were significantly lower in ezetimibe- plus-atorvastatin group compared to danble-dose atorvastatin group. The LDL-C level of double-dose atorvastatin re-increased after 12 weeks, while LDL-C reduction was stable for 24 weeks. Conclusion： The patients with coronary artery disease whole LDL-C levels didn＇ t achieve therapeutic goal after received routine statin took better plus ezetimible, because cholesterol and provide stable decrease in LDL-C levds. could simultaneously inhibit the absorption and synthesis of
出处
《中国医学创新》
CAS
2013年第12期50-52,共3页
Medical Innovation of China
关键词
依折麦布
阿托伐他汀
低密度脂蛋白
冠状动脉疾病
Ezetimibe
Atorvastatin
Low density lipoprotein-cholesterol
Coronary artery disease
